Antithrombin Market Size, Share & Industry Analysis, By Source (Human Plasma and Others), By Application (Therapeutic and Research & Diagnostic), By Dosage Form (Lyophilized Powder and Liquid), By End User (Hospitals & Clinics, Pharmaceutical & Biotechnology Industry, and Research Institutes), and Regional Forecast, 2025-2032

The global antithrombin market size was valued at USD 373.9 million in 2024. The market is projected to grow from USD 388.2 million in 2025 to USD 519.9 million by 2032, exhibiting a CAGR of 4.3% during the forecast period.Europe dominated the antithrombin market  with a market share of 42.28% in 2024.

Antithrombin, a glycoprotein that inactivates thrombin and other serine proteases, plays a vital role in preventing abnormal blood clotting. It is especially critical for patients with hereditary antithrombin deficiency, undergoing surgery, or requiring Extracorporeal Membrane Oxygenation (ECMO). The market is experiencing steady growth throughout the study period with a moderate CAGR.

Some of the factors driving the market growth are the increasing prevalence of thrombotic disorders, advancements in biotechnology, and a surge in the demand for anticoagulant therapies. The prevalence of AT deficiency among the general population is also increasing, leading to the growing demand for product concentrates for treatment.

• For instance, according to a study published in the National Center for Biotechnology Information (NCBI) by Spanish researchers in September 2023, the estimated prevalence of Hereditary AT deficiency is between 0.02% and 0.2% among the general population.

Key players operating in the market include CSL, Grifols, S.A., Octapharma AG, and others. The strong presence of these companies in plasma-derived medicinal products, including antithrombin, supports the market growth.

MARKET DYNAMICS:

MARKET DRIVERS:

Expanding Applications of Antithrombin to Boost Market Growth

One of the prominent factors that has driven the antithrombin market growth is the expanding applications of antithrombin. The use of these products is being researched for indications beyond thrombosis, including preeclampsia and organ transplantation. Some of its potential applications include COVID-19 infection, Continuous Renal Replacement Therapy (CRRT), Asparaginase therapy for Acute Lymphoblastic Leukemia (ALL), modulation of tumor cell activity, and management of hemorrhagic shock. Such scenarios are anticipated to boost the market growth in the coming years.

• For instance, according to a study published by the National Center for Biotechnology Information (NCBI) in October 2022, the anti-thromboinflammatory properties of antithrombin have the potential to reduce mortality associated with persistent hypercoagulable and pro-inflammatory states in severe COVID-19 patients.

MARKET RESTRAINTS:

Concerns Associated With Antithrombin Therapy to Hinder Market Growth

Despite the usage of antithrombin growth, the concerns and adverse effects associated hinder the adoption of the product. Some of the potential concerns include the risk of bleeding, allergic & anaphylactic reactions, thromboembolic complications, and others. This results in limited usage of antithrombin replacement therapy, in turn, hampering the overall market growth.

MARKET OPPORTUNITIES:

Adoption of Antithrombin as a Combination Therapy with Other Therapeutics to Create Lucrative Growth Opportunities

The growing trend of combining antithrombin with heparin for enhanced anticoagulant effects is anticipated to create a lucrative growth opportunity in the market. A number of research studies have been published to demonstrate the potential of antithrombin in combination therapies. The combination of heparin and antithrombin exhibits a synergistic effect, depicting that their combined anticoagulant effect is greater than the sum of their individual effects. Thus, the market is witnessing a positive shift toward the use of antithrombin in combination therapy, especially with heparin.

MARKET CHALLENGES:

High Cost of Treatment to Limit Market Growth

High pricing of antithrombin products is considered a major limiting factor for the market growth. The availability of conventional & substitute anticoagulant therapeutics negatively impacts the adoption of antithrombin products. Some of the alternatives include heparin, direct thrombin inhibitors such as Argatroban, Direct Oral Anticoagulants including Eliquis, and others. In low-and-middle income countries, the high prices make it less affordable to the patient population.

Other Challenges:

Some of the other challenges include the complex manufacturing of plasma-derived products, including antithrombin, which is highly regulated and expensive. In addition, a stringent regulatory framework resulting in long approval timelines in major regions such as the U.S., EU, and Japan also challenges market growth. Furthermore, plasma-derived products depend on donor availability, affecting consistency and global supply.

ANTITHROMBIN MARKET TRENDS:

Increasing Usage of Antithrombin in Surgical Procedures is Identified as one of the Significant Market Trends

The rising number of cardiovascular, transplant, and neonatal surgeries is expanding antithrombin usage. This is particularly true in patients who have heparin resistance or antithrombin deficiency. Additionally, antithrombin concentrate also prevents thrombosis of the hepatic artery following orthotopic liver transplantation, a surgery where a diseased liver is replaced with a healthy one from a deceased or living donor. Thus, the market is witnessing a significant increase in the usage of antithrombin concentrates in various surgical procedures, in turn driving the market growth to a certain extent.

Request a Free sample to learn more about this report.

IMPACT OF COVID-19:

As a result of the COVID-19 pandemic, the global market experienced slightly more positive growth than in 2019. This can be attributed to the increased use of antithrombin products in the treatment of severe COVID-19 patients. Several research studies have demonstrated that antithrombin therapy plays an important role in the thromboinflammatory processes associated with severe COVID-19.

Segmentation Analysis

By Source

Robust Product Offerings based on Human Plasma Proliferated Segment Growth

On the basis of source, the market is segmented into human plasma and others.

The human plasma segment captured the largest antithrombin market share in 2024. This can be attributed to factors such as the wide availability of products that are derived from human plasma. Additionally, the increasing prevalence of antithrombin deficiency coupled with the increasing number of cardiac surgeries where antithrombin concentrates play a vital role in supplementing segmental growth.

• For instance, as per an article published by Annals of Thoracic Surgery Short Reports in June 2024, in the U.S., the average total cardiac surgical volume was 271.5 per 100,000 population per year. This was comparatively higher than the global average of 123.2 per 100,000 population per year.

Furthermore, the others segment, which includes recombinant antithrombin, is anticipated to grow at a moderate rate in the coming years. Limited approvals for recombinant products have resulted in lower adoption in the market.

• For instance, in September 2017, Kyowa Hakko Kirin Co., Ltd. received manufacturing and marketing approval for its ACOALAN injection 1800 from the Ministry of Health, Labor and Welfare in Japan. It is an antithrombin (AT) drug manufactured using the technology of recombinant DNA and sugar-chain control.

To know how our report can help streamline your business, Speak to Analyst

By Application

High Adoption of Antithrombin for Therapeutic Purposes Impelled Segment Growth

In terms of application, the global market is segmented into therapeutic and research & diagnostic.

The therapeutic segment dominated the global market share in 2024. The increasing demand for efficient treatment using antithrombin concentrate has resulted in increased demand for these products across the world. Additionally, considerable usage of antithrombin to cure patients with heparin resistance is also supporting segmental growth.

• For instance, according to the data from the American Society of Hematology, published in December 2024, antithrombin supplementation is one of the preferred treatment choices for managing patients with heparin resistance.

On the other hand, the research & diagnostic usable segment is anticipated to grow at a moderate CAGR in the coming years. Factors supporting this growth include the availability of a few products that can be used for diagnostic and research purposes.

By Dosage Form

Wide Availability of Products in Lyophilized Form Supported Segment’s Dominance

Based on dosage form, the global market is categorized into lyophilized powder and liquid.

The lyophilized powder segment held the leading position in the global market in 2024. The majority of the currently available products of antithrombin concentrates are present in the lyophilized powder form. Several factors, such as ease of handling, improved stability of the product due to lyophilized form, and others, have supplemented the use of these products for various applications.

• For instance, products such as THROMBATE III from Grifols, Thrombotrol VF from CSL, Atenativ from Octapharma AG, and others are in the form of lyophilized powder.

Contrastingly, the liquid segment held a very low share of the market owing to the presence of only one product. Scripps Laboratory is the only company that provides antithrombin concentrates in the form of liquid.

By End User

High Demand from Hospitals & Clinics for Therapeutic Usage Boosted Segment Growth

On the basis of end user, the global market is divided into hospitals & clinics, pharmaceutical & biotechnology industry, and research institutes.

The hospitals & clinics segment held the highest share of the market in 2024. This can be attributed to the increasing usage of antithrombin-based treatments in conditions such as antithrombin deficiency, heparin resistance, sepsis, and others.

The pharmaceutical & biotechnology industry segment is poised to grow at a considerable CAGR during the forecast period. The segment growth can be attributed to the increasing usage of antithrombin concentrates for research purposes.

ANTITHROMBIN REGIONAL OUTLOOK

In terms of regions, the market is segmented into Europe, Asia Pacific, North America, and the rest of the world.

Europe:

Europe Dominated the Market Due to a High Number of Approved Products and a Strong Presence of Well-Established Players

To get more information on the regional analysis of this market, Request a Free sample

Europe’s market was valued at USD 158.9 million in 2024 and is expected to maintain its dominance throughout the forecast period. The high number of approved products, the strong presence of well-established players, and the increasing prevalence of antithrombin deficiency are some of the key aspects supporting the dominance of the region in the global market. Europe has witnessed remarkable growth in Plasma-Derived Medicinal Products Manufacturing (PDMP) with a surge in new capacity installations and strategic initiatives.

• For instance, in July 2022, plasma donor centers at Reading, Birmingham, and London installed new ‘female friendly’ donor machines, doubling the number of women who can donate lifesaving plasma.

Asia Pacific:

On the other hand, Asia Pacific is projected to exhibit the highest CAGR over the forecast period. This growth is attributed to the increasing number of cases of congenital antithrombin deficiency and, consequently, increasing the demand for antithrombin concentrates in the region. Additionally, strategic initiatives undertaken by regional companies to expand their market presence are another key factor supplementing the Asia Pacific antithrombin market growth.

• For instance, in May 2023, Plasma Gen Biosciences opened a new, state-of-the-art manufacturing facility for blood plasma products in Bangalore, India, to fulfill the growing demand for plasma-based products at affordable prices.

North America:

The antithrombin market in the North America region held a comparatively lower share. This is majorly due to the limited availability of antithrombin concentrates in the region. Additionally, stringent regulatory guidelines for plasma derived products in the U.S. also impacted the regional market growth.

Rest of the World:

The market in the rest of the world region is predicted to grow at a slower CAGR over the forecast period. This can be attributed to the limited presence of antithrombin concentrate products in these regions. All the currently marketed products in Brazil, Mexico, South Africa, and other countries, are derived from the human plasma fractionation method only.

COMPETITIVE LANDSCAPE:

Key Market Players:

Key Players in the Market Focus on Strengthening their Product Offering to Sustain Market Competition

CSL is one of the prominent players in the market with a substantial share of the global market. The company’s dominance is majorly due to the strong product portfolio of the company for human plasma-derived antithrombin products. Furthermore, the company’s leading position in plasma-derived medicinal products also supports its leading position in the antithrombin market.

Grifols, S.A. is another leading manufacturer of plasma-derived antithrombin concentrates. The high market share is attributed to its robust focus on the expansion of current applications of antithrombin concentrates and collaborations with pharmaceutical companies.

Other key market players operating at the global level are Octapharma AG, Owen Takeda Pharmaceutical Company Limited, and Kedrion S.p.A and others. These companies are undertaking various strategic initiatives to maintain their market positions.

LIST OF KEY ANTITHROMBIN COMPANIES PROFILED:

• CSL (Australia)


• Octapharma AG (Switzerland)


• Takeda Pharmaceutical Company Limited (Japan)


• Grifols, S.A. (Spain)


• Medix Biochemica (Finland)


• Kedrion S.p.A (Italy)


• Scripps Laboratories (U.S.)


• LFB (France)

KEY INDUSTRY DEVELOPMENTS:

• June 2023: Octapharma AG showcased a poster on a prospective, phase III study of the efficacy, safety, and pharmacokinetics of a human antithrombin III concentrate in congenital antithrombin deficiency during surgery or childbirth by Craig Kessler.


• June 2022: Endpoint Health Inc. raised funding of USD 52 million for the expansion of its precision immunology pipeline. This includes the Antithrombin III program, a Phase II clinical trial for the treatment of sepsis.


• November 2021: Octapharma AG received approval from the U.S. FDA to proceed with clinical studies of ATN-106ATN-106. The study aims to establish the safety and efficacy of the company’s antithrombin concentrate for the treatment of patients with congenital antithrombin deficiency. 


• September 2019: SK Pharma, a producer of blood products from South Korea, signed a Memorandum of Understanding (MOU) with the Indonesian pharmaceutical company BioPharma and the Indonesian Red Cross for blood plasma production.


• September 2017: Kyowa Hakko Kirin Co., Ltd. received manufacturing and marketing approval for its ACOALAN injection 1800 from the Ministry of Health, Labor and Welfare in Japan.

REPORT COVERAGE

The global antithrombin market research report provides a detailed and comprehensive analysis of the market. Some of the key insights that the report provides include, the prevalence of key cardiac diseases by key countries, regulatory overview of these products by key countries/regions, recent industry developments, and the impact of COVID-19 on the market. The research report also includes the key market dynamics that have contributed to the growth of the market across the forecast period. The report also encompasses the profiles of the major companies operating in the market and the global competitive landscape.

To gain extensive insights into the market, Request for Customization

Report Scope & Segmentation